查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1830883

2025年全球放射性配体疗法市场报告

Radioligand Therapy Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，放射性配体疗法市场发展迅速，预计从2024年的60.1亿美元成长到2025年的66.4亿美元，复合年增长率达10.5%。预测期内的成长主要归功于液态切片的日益普及、肿瘤诊断疗法的出现、人工智慧在肿瘤学领域的应用、双特异性抗体研发管线的不断扩大以及政府对癌症研究投入的增加。

预计未来几年放射性配体疗法市场将快速成长，到2029年市场规模将达到97.7亿美元，复合年增长率（CAGR）为10.2%。推动预测期内市场成长的因素包括：大型製药企业加大对肿瘤新兴企业的投资、更多地利用真实世界证据、放射性药物和治疗诊断学领域的研究不断拓展、产学研合作日益加强，以及罕见疾病和孤儿癌发病率不断上升。这段时期的主要发展趋势包括：基于人工智慧的放射性药物设计、结合成像和治疗平台的诊疗治疗诊断学、基于微流体的放射性示踪剂合成、下一代α发射同位素的开发以及3D列印的个人化剂量测定设备。

放射性配体疗法（RLT）是一种先进的标靶癌症治疗方法，它将放射性同位素连接到专门设计的配体上，该配体能够与癌细胞上的受体结合。 RLT 给药后，可针对癌细胞，将精确的辐射直接输送到癌细胞，同时最大限度地减少对健康组织的损伤。这种标靶机制可以减少副作用并提高治疗效果，尤其适用于对传统治疗方法抗药性的病例。

放射性配体疗法（RLT）中使用的主要放射性配体包括α粒子发射体、β粒子发射体、俄歇粒子发射体和复合粒子发射体。 α粒子发射体可在极短距离内（通常仅穿透几个细胞层）发射高能量α粒子，因此能够高效地精确破坏细胞。这些放射性配体分子标靶，例如荷尔蒙受体、生长因子受体和肿瘤抗原标记。给药途径多种多样，包括静脉注射。放射性配体疗法用于治疗多种疾病，包括癌症、心血管疾病、神经系统疾病和感染疾病，并广泛应用于医院、诊断实验室、研究机构和居家医疗机构。

2025年，美国关税的突然上涨及其引发的贸易摩擦对製药公司造成了严重衝击，这些公司正努力应对原料药、玻璃瓶和实验室设备等产品的关税问题。利润率高的学名药生产商尤其脆弱，一些公司不得不缩减低利润药物的生产规模。生物技术公司也因关税导致的特种试剂短缺而面临临床试验延期的困境。为了应对这一局面，製药业正在印度和欧洲扩大原料药的生产，增加库存，并游说政府对基本药物给予贸易豁免。

本研究报告是商业研究公司（The Business Research Company）最新系列报告的一部分，提供放射性配体疗法市场统计数据，包括全球市场规模、区域份额、竞争对手及其市场份额、详细的市场细分、市场趋势以及放射性配体疗法行业的商机，为您提供在该行业取得成功所需的关键数据。本市场研究报告对该行业的现状和未来发展趋势进行了深入分析，为您提供全面的观点。

预计未来几年，癌症发生率的上升将推动放射性配体疗法市场的成长。癌症的特征是异常细胞不受控制地增殖，侵入周围组织并扩散至全身。癌症患者数量的增加与长期暴露于环境污染物密切相关，这些污染物会损伤DNA、破坏细胞功能并促进异常细胞生长。放射性配体疗法透过配体与特定受体结合，利用辐射靶向癌细胞，从内部破坏癌细胞，同时最大限度地减少对健康组织的损伤。例如，根据美国癌症协会（美国非营利组织）预测，2022年1月美国预计将新增约190万例癌症病例和609,360例癌症相关死亡病例，相当于每天约有1,670人死亡。因此，癌症盛行率的上升推动了放射性配体疗法市场的扩张。

放射性配体疗法市场的企业正日益重视开发先进的生产设施，以提高生产效率，同时确保标靶癌症治疗药物在生产和分销过程中始终保持品质和安全标准。放射性配体疗法生产设施是专门用于处理和交付靶向癌症治疗放射性药物的中心，配备先进的成像系统和辐射屏蔽设备、训练有素的人员以及严格的安全通讯协定。例如，总部位于瑞士的製药公司诺华公司于2024年1月宣布，其位于印第安纳州的新型大型放射性配体疗法（RLT）生产工厂已实现自动化，并获得美国食品药物管理局（FDA）的商业化生产批准。这座占地7万平方英尺的工厂是诺华公司规模最大、技术最先进的RLT专用生产设施，配备了全自动生产线，旨在高效、及时地生产，以满足美国和加拿大日益增长的患者需求。

2023年12月，美国製药公司礼来（Eli Lilly and Company）以14亿美元收购了POINT Biopharma Global Inc.。此次收购增强了礼来在肿瘤领域的实力，并整合了先进的放射性配体疗法技术，从而提升了精准癌症治疗方案的选择范围。 POINT Biopharma Global Inc.同样总部位于美国，专注于开髮用于癌症治疗的放射性配体疗法。

放射性配体治疗市场由提供标靶治疗服务、诊断影像服务以及临床和基础设施服务等服务的营业单位所获得的收入所构成。市场价值还包括服务提供者销售的或包含在其服务产品中的相关产品的价值。放射性配体治疗市场还包括生长抑制素受体配体、放射性标记的铃蟾肽类似物、放射性标记的单株抗体以及前列腺特异性膜抗原 (PSMA) 靶向配体的销售。该市场的价值为“出厂价”，即产品製造商或创造者销售的产品价值，无论销售对像是其他营业单位（包括下游製造商、批发商、经销商和零售商）还是直接销售给最终客户。该市场的产品价值还包括产品创造者提供的任何相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球放射性配体疗法：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 终端用户产业分析
  • 全球放射性配体治疗市场：成长率分析
  • 全球放射性配体疗法市场表现：规模与成长，2019-2024年
  • 全球放射性配体疗法市场预测：规模与成长，2024-2029年，2034年
  • 全球放射性配体疗法：潜在市场规模 (TAM)

第六章 市场细分

  • 全球放射性配体疗法市场按类型、性能和预测划分，2019-2024年、2024-2029年、2034年
  • 阿尔法发射体
  • β射线放射体
  • 俄歇辐射发射器
  • 复合散热器
  • 全球放射性配体疗法市场按分子标靶靶、性能和预测划分，2019-2024年、2024-2029年和2034年
  • 荷尔蒙受体
  • 生长因子受体
  • 抗原肿瘤标记
  • 其他的
  • 全球放射性配体疗法市场依给药途径、效能及预测划分，2019-2024年、2024-2029年、2034年
  • 静脉注射（IV）
  • 肌肉内注射（IM）
  • 皮下
  • 口服
  • 全球放射性配体疗法市场：依应用、效能和预测划分，2019-2024年、2024-2029年、2034年
  • 癌症
  • 心血管疾病
  • 神经系统疾病
  • 感染疾病
  • 全球放射性配体治疗市场（依最终使用者、表现和预测划分，2019-2024年、2024-2029年、2034年）
  • 医院
  • 诊断实验室
  • 研究所
  • 居家医疗
  • 全球放射性配体治疗市场：α发射体细分市场，按类型、性能和预测，2019-2024年、2024-2029年、2034年
  • 锕-225 (Ac-225)
  • 镭-223（Ra-223）
  • 砹-211（At-211）
  • 铋-213（Bi-213）
  • 全球放射性配体治疗市场：β发射体细分市场，按类型、性能和预测，2019-2024年、2024-2029年、2034年
  • 镏-177（Lu-177）
  • 碘-131 (I-131)
  • 钇-90 (Y-90)
  • 钐-153 (Sm-153)
  • 全球放射性配体治疗市场：俄歇发射器细分市场，按类型、性能和预测（2019-2024年、2024-2029年、2034年）
  • 碘-125 (I-125)
  • 铟-111 (In-111)
  • 镓-67（Ga-67）
  • 铊-201 (Tl-201)
  • 全球放射性配体治疗市场：多发射体细分市场，按类型、性能和预测，2019-2024年、2024-2029年、2034年
  • 铽-161 (Tb-161)
  • 铜-67（Cu-67）
  • 铼-186 (Re-186)
  • 铅-212 (Pb-212)

第七章 区域和国家分析

  • 全球放射性配体治疗市场：依地区、绩效及预测划分，2019-2024年、2024-2029年、2034年
  • 全球放射性配体治疗市场：国家、绩效及预测，2019-2024年、2024-2029年、2034年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

  • 放射性配体疗法市场：竞争格局
  • 放射性配体治疗市场：公司概况
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
    • Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Curium LLC Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Eckert & Ziegler Strahlen-und Medizintechnik AG
  • Molecular Partners AG
  • Telix Pharmaceuticals
  • Nanobiotix SA
  • Mariana Oncology Inc.
  • Artios Pharma Limited
  • AdvanCell Pty Ltd.
  • Evergreen Theragnostics Inc.
  • Fusion Pharmaceuticals Inc.
  • RadioMedix Inc.
  • Ariceum Therapeutics GmbH
  • Radiopharm Theranostics Limited
  • Convergent Therapeutics Inc.
  • C-Ray Therapeutics Inc.
  • OncoSil Medical Ltd.

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第35章：高潜力市场国家、细分市场与策略

  • 2029年放射性配体疗法市场：提供新机会的国家
  • 放射性配体治疗市场展望 2029：新兴细分市场机会
  • 放射性配体疗法市场2029年：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章附录

简介目录
Product Code: r37874

Radioligand therapy (RLT) is an advanced targeted cancer treatment that attaches a radioactive isotope to a ligand specifically designed to bind to cancer cell receptors. Once administered, it targets tumor cells and delivers precise radiation directly to them, minimizing damage to healthy tissues. This targeted mechanism helps reduce side effects and enhances treatment outcomes, particularly in cases resistant to conventional therapies.

The primary types of radioligands used in RLT include alpha emitters, beta emitters, Auger emitters, and combined emission radioligands. Alpha emitters release high-energy alpha particles over very short distances, typically a few cell layers, making them highly effective for precise cell destruction. These radioligands are engineered to bind to specific molecular targets, such as hormone receptors, growth factor receptors, tumor antigen markers, and others. They can be administered via multiple routes, including intravenous (IV), intramuscular (IM), subcutaneous, and oral. Radioligand therapy is applied in treating a variety of conditions, including oncological and cardiovascular disorders, neurological diseases, and infectious diseases, and is utilized across hospitals, diagnostic laboratories, research institutions, and home care settings.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The radioligand therapy market research report is one of a series of new reports from The Business Research Company that provides radioligand therapy market statistics, including the radioligand therapy industry global market size, regional shares, competitors with the radioligand therapy market share, detailed radioligand therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the Radioligand therapy industry. This radioligand therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The radioligand therapy market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.64 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to the increasing use of liquid biopsies, the emergence of tumor-agnostic therapies, the integration of artificial intelligence in oncology, the expanding pipeline of bispecific antibodies, and the rise in government funding for cancer research.

The radioligand therapy market size is expected to see rapid growth in the next few years. It will grow to $9.77 billion in 2029 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to increasing investments by major pharmaceutical companies in oncology startups, greater utilization of real-world evidence, expansion of research in radiopharmaceuticals and theranostics, strengthened collaborations between academia and industry, and the rising prevalence of rare and orphan cancers. Key trends expected during this period include AI-driven design of radiopharmaceuticals, theranostics with combined imaging and therapy platforms, microfluidics-based radiotracer synthesis, development of next-generation alpha-emitting isotopes, and 3D-printed personalized dosimetry devices.

The rising incidence of cancer is expected to drive growth in the radioligand therapy market in the coming years. Cancer is characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread throughout the body. The increase in cancer cases is linked to long-term exposure to environmental pollutants that damage DNA, disrupt cellular function, and promote abnormal cell proliferation. Radioligand therapy addresses cancer by delivering targeted radiation to tumor cells via ligands that bind to specific receptors, minimizing damage to healthy tissues while destroying cancer cells internally. For example, in January 2022, the American Cancer Society, a U.S.-based non-profit organization, reported that approximately 1.9 million new cancer cases and 609,360 cancer-related deaths were expected in the U.S., translating to roughly 1,670 deaths per day. Therefore, the growing prevalence of cancer is supporting the expansion of the radioligand therapy market.

Companies in the radioligand therapy market are increasingly focusing on the development of advanced facilities to improve production efficiency while ensuring consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers equipped to handle and deliver radioactive drugs for targeted cancer therapy, employing advanced imaging systems and radiation shielding, along with trained personnel and strict safety protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana, which received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, featuring fully automated production lines designed for efficient, time-sensitive manufacturing to meet rising patient demand in the U.S. and Canada.

In December 2023, Eli Lilly and Company, a U.S.-based pharmaceutical firm, acquired POINT Biopharma Global Inc. for \$1.4 billion. This acquisition strengthens Eli Lilly's oncology portfolio by integrating advanced radioligand therapy capabilities to enhance precision cancer treatment options. POINT Biopharma Global Inc., also based in the U.S., specializes in the development of radioligand therapies for cancer.

Major players in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc., OncoSil Medical Ltd.

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the radioligand therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The radioligand therapy market consists of revenues earned by entities by providing services such as targeted treatment services, diagnostic imaging, and clinical and infrastructure services. The market value includes the value of related goods sold by the service provider or included within the service offering. The radioligand therapy market also includes sales of somatostatin receptor ligands, radiolabeled bombesin analogs, radiolabeled monoclonal antibodies, and prostate-specific membrane antigen (PSMA)-targeted ligands. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Radioligand Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on radioligand therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for radioligand therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The radioligand therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type Of Radioligand: Alpha Emitters; Beta Emitters; Auger Emitters; Combined Emissions
  • 2) By Molecular Target: Hormone Receptors; Growth Factor Receptors; Antigen Tumor Markers; Other Molecular Targets
  • 3) By Route Of Administration: Intravenous (IV); Intramuscular (IM); Subcutaneous; Oral
  • 4) By Application: Oncology; Cardiovascular Disorders; Neurological Disorders; Infectious Diseases
  • 5) By End-User: Hospitals; Diagnostic Laboratories; Research Institutions; Home Care Settings
  • Subsegments:
  • 1) By Alpha Emitters: Actinium-225 (Ac-225); Radium-223 (Ra-223); Astatine-211 (At-211); Bismuth-213 (Bi-213)
  • 2) By Beta Emitters: Lutetium-177 (Lu-177); Iodine-131 (I-131); Yttrium-90 (Y-90); Samarium-153 (Sm-153)
  • 3) By Auger Emitters: Iodine-125 (I-125); Indium-111 (In-111); Gallium-67 (Ga-67); Thallium-201 (Tl-201)
  • 4) By Combined Emissions: Terbium-161 (Tb-161); Copper-67 (Cu-67); Rhenium-186 (Re-186); Lead-212 (Pb-212)
  • Companies Mentioned: Bayer AG; Novartis AG; Eli Lilly and Company; Lantheus Holdings Inc.; Curium LLC; Eckert & Ziegler Strahlen- und Medizintechnik AG; Molecular Partners AG; Telix Pharmaceuticals; Nanobiotix S.A.; Mariana Oncology Inc.; Artios Pharma Limited; AdvanCell Pty Ltd.; Evergreen Theragnostics Inc.; Fusion Pharmaceuticals Inc.; RadioMedix Inc.; Ariceum Therapeutics GmbH; Radiopharm Theranostics Limited; Convergent Therapeutics Inc.; C-Ray Therapeutics Inc.; OncoSil Medical Ltd.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Radioligand Therapy Market Characteristics

3. Radioligand Therapy Market Trends And Strategies

4. Radioligand Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Radioligand Therapy Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Radioligand Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Radioligand Therapy Market Growth Rate Analysis
  • 5.4. Global Radioligand Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Radioligand Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Radioligand Therapy Total Addressable Market (TAM)

6. Radioligand Therapy Market Segmentation

  • 6.1. Global Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpha Emitters
  • Beta Emitters
  • Auger Emitters
  • Combined Emissions
  • 6.2. Global Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Receptors
  • Growth Factor Receptors
  • Antigen Tumor Markers
  • Other Molecular Targets
  • 6.3. Global Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous (IV)
  • Intramuscular (IM)
  • Subcutaneous
  • Oral
  • 6.4. Global Radioligand Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oncology
  • Cardiovascular Disorders
  • Neurological Disorders
  • Infectious Diseases
  • 6.5. Global Radioligand Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Diagnostic Laboratories
  • Research Institutions
  • Home Care Settings
  • 6.6. Global Radioligand Therapy Market, Sub-Segmentation Of Alpha Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Actinium-225 (Ac-225)
  • Radium-223 (Ra-223)
  • Astatine-211 (At-211)
  • Bismuth-213 (Bi-213)
  • 6.7. Global Radioligand Therapy Market, Sub-Segmentation Of Beta Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lutetium-177 (Lu-177)
  • Iodine-131 (I-131)
  • Yttrium-90 (Y-90)
  • Samarium-153 (Sm-153)
  • 6.8. Global Radioligand Therapy Market, Sub-Segmentation Of Auger Emitters, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Iodine-125 (I-125)
  • Indium-111 (In-111)
  • Gallium-67 (Ga-67)
  • Thallium-201 (Tl-201)
  • 6.9. Global Radioligand Therapy Market, Sub-Segmentation Of Combined Emissions, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Terbium-161 (Tb-161)
  • Copper-67 (Cu-67)
  • Rhenium-186 (Re-186)
  • Lead-212 (Pb-212)

7. Radioligand Therapy Market Regional And Country Analysis

  • 7.1. Global Radioligand Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Radioligand Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Radioligand Therapy Market

  • 8.1. Asia-Pacific Radioligand Therapy Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Radioligand Therapy Market

  • 9.1. China Radioligand Therapy Market Overview
  • 9.2. China Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Radioligand Therapy Market

  • 10.1. India Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Radioligand Therapy Market

  • 11.1. Japan Radioligand Therapy Market Overview
  • 11.2. Japan Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Radioligand Therapy Market

  • 12.1. Australia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Radioligand Therapy Market

  • 13.1. Indonesia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Radioligand Therapy Market

  • 14.1. South Korea Radioligand Therapy Market Overview
  • 14.2. South Korea Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Radioligand Therapy Market

  • 15.1. Western Europe Radioligand Therapy Market Overview
  • 15.2. Western Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Radioligand Therapy Market

  • 16.1. UK Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Radioligand Therapy Market

  • 17.1. Germany Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Radioligand Therapy Market

  • 18.1. France Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Radioligand Therapy Market

  • 19.1. Italy Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Radioligand Therapy Market

  • 20.1. Spain Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Radioligand Therapy Market

  • 21.1. Eastern Europe Radioligand Therapy Market Overview
  • 21.2. Eastern Europe Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Radioligand Therapy Market

  • 22.1. Russia Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Radioligand Therapy Market

  • 23.1. North America Radioligand Therapy Market Overview
  • 23.2. North America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Radioligand Therapy Market

  • 24.1. USA Radioligand Therapy Market Overview
  • 24.2. USA Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Radioligand Therapy Market

  • 25.1. Canada Radioligand Therapy Market Overview
  • 25.2. Canada Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Radioligand Therapy Market

  • 26.1. South America Radioligand Therapy Market Overview
  • 26.2. South America Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Radioligand Therapy Market

  • 27.1. Brazil Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Radioligand Therapy Market

  • 28.1. Middle East Radioligand Therapy Market Overview
  • 28.2. Middle East Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Radioligand Therapy Market

  • 29.1. Africa Radioligand Therapy Market Overview
  • 29.2. Africa Radioligand Therapy Market, Segmentation By Type Of Radioligand, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Radioligand Therapy Market, Segmentation By Molecular Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Radioligand Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Radioligand Therapy Market Competitive Landscape And Company Profiles

  • 30.1. Radioligand Therapy Market Competitive Landscape
  • 30.2. Radioligand Therapy Market Company Profiles
    • 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Lantheus Holdings Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Curium LLC Overview, Products and Services, Strategy and Financial Analysis

31. Radioligand Therapy Market Other Major And Innovative Companies

  • 31.1. Eckert & Ziegler Strahlen- und Medizintechnik AG
  • 31.2. Molecular Partners AG
  • 31.3. Telix Pharmaceuticals
  • 31.4. Nanobiotix S.A.
  • 31.5. Mariana Oncology Inc.
  • 31.6. Artios Pharma Limited
  • 31.7. AdvanCell Pty Ltd.
  • 31.8. Evergreen Theragnostics Inc.
  • 31.9. Fusion Pharmaceuticals Inc.
  • 31.10. RadioMedix Inc.
  • 31.11. Ariceum Therapeutics GmbH
  • 31.12. Radiopharm Theranostics Limited
  • 31.13. Convergent Therapeutics Inc.
  • 31.14. C-Ray Therapeutics Inc.
  • 31.15. OncoSil Medical Ltd.

32. Global Radioligand Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Radioligand Therapy Market

34. Recent Developments In The Radioligand Therapy Market

35. Radioligand Therapy Market High Potential Countries, Segments and Strategies

  • 35.1 Radioligand Therapy Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Radioligand Therapy Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Radioligand Therapy Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer